Sunday, July 12, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 45 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 10435355

    Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments

    The Regents of the University of California · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted
  2. US 10435399

    HDAC6 inhibitory heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted
  3. US 10434075

    FKBP52 specific androgen receptor inhibitor, MJC13, for use in treating breast cancer

    The Board of Regents of the University of Texas System · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted
  4. US 10434096

    Tyrosine kinase inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted
  5. US 10428157

    Dosing regimens for use with PCSK9 inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  6. US 10428057

    Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease

    The Board of Regents of the University of Texas System · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  7. US 10426767

    Methods of treating cancer with farnesyltransferase inhibitors

    Kura Oncolofy, Inc. · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  8. US 10428028

    HDAC inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  9. US 10428050

    Substituted reverse pyrimidine Bmi-1 inhibitors

    PTC THERAPEUTICS, INC. · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  10. US 10420813

    Competitive inhibitors of invariant chain expression and/or ectopic clip binding

    The Regents of the University of Colorado, a Body Corporate · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted
  11. US 10421802

    Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted
  12. US 10421765

    Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase

    The Board of Regents of the University of Texas System · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted
  13. US 10420758

    Indolinyl-sulfonamide inhibitors of tankyrase and methods of use thereof

    The Board of Regents of the University of Texas System · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted
  14. US 10414740

    Glutaminase inhibitors and method of use

    Agios Pharmaceuticals, Inc. · Granted Sep 17, 2019 · Expires Sep 12, 2039

    granted
  15. US 10416163

    Method and treatment of recurring endometrial cancer with an inhibitor of USP14

    Regents of the University of Minnesota · Granted Sep 17, 2019 · Expires Sep 12, 2039

    granted
  16. US 10407445

    Hepatitis C virus inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  17. US 10407409

    6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD

    Takeda Pharmaceutical Company Limited · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  18. US 10406148

    Methods of treatment using a JAK inhibitor compound

    Theravance Biopharma R&D IP, LLC · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  19. US 10400010

    Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics

    The Regents of the University of California · Granted Sep 3, 2019 · Expires Aug 29, 2039

    granted
  20. US 10398706

    Heteroaryldiazepine derivatives as RSV inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Sep 3, 2019 · Expires Aug 29, 2039

    granted
  21. US 10392386

    JAK inhibitors containing a 4-membered heterocyclic amide

    Theravance Biopharma R&D IP, LLC · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted
  22. US 10392391

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted
  23. US 10391175

    BET bromodomain inhibitors and therapeutic methods using the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted
  24. US 10391095

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted